Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 61-70 of 144 for Ovarian

Edit search filters
  1. Study To Compare The Safety And Effectiveness Of Treatment Combinations In Patients With Recurrent Ovarian Cancer

    Rochester, MN

  2. Study Of E7386 In Participants With Selected Advanced Neoplasms

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. A First-in-Human Study Of MEN2501 In Participants With Platinum-Resistant Ovarian Cancer

    Rochester, MN

  4. OTL38 For Intra-operative Imaging Of Folate Receptor Positive Ovarian Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN

  5. Olaparib Monotherapy In Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

    Rochester, MN

  6. A Study Of Niraparib In Patients With Ovarian Cancer Who Have Received Three Or Four Previous Chemotherapy Regimens

    Rochester, MN

  7. Everolimus And Letrozole In Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, Or Primary Peritoneal Cavity Cancer

    Jacksonville, FL, Rochester, MN

  8. Gemcitabine Hydrochloride Alone Or With M6620 In Treating Patients With Recurrent Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer

    Rochester, MN

  9. Study Of The Safety, Pharmacokinetics And Efficacy Of EDO-S101, In Patients With Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Rochester, MN

  10. Veliparib And Topotecan Hydrochloride In Treating Patients With Solid Tumors, Relapsed Or Refractory Ovarian Cancer, Or Primary Peritoneal Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer